Search
SOLACI Congress
HomeFile

File

View Category
Acute coronary syndromes

EuroPCR 2025 | Multivessel PCI in Cardiogenic Shock: A Substudy from the DanGer Shock

Patients with extensive acute myocardial infarctions may develop cardiogenic shock, which has been associated with marked contractile...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

EuroPCR 2025 | 10-Year Follow-up of DANAMI-3-PRIMULTI: Complete vs. Culprit-Only Revascularization in STEMI with Multivessel Disease

The DANAMI-3-PRIMULTI trial included 627 patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD),...
solaci -
Learn More
Structural Heart Disease

EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

Stroke remains a significant complication associated with the various transcatheter aortic valve implantation (TAVI) devices currently in...
Dr. Omar Tupayachi -
Learn More
Chronic Ischemic cardiopathy

EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI)

Coronary artery disease is present in 50 to 70% of TAVI candidates and over 90% of these...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Platelet inhibition during and after coronary angioplasty is essential to prevent peri- and post-procedural ischemic events. To...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

One-Year Mortality Trends Following TAVR: STS/ACC TVT Registry Outcomes

Transcatheter aortic valve replacement (TAVR) has quickly consolidated as a safe and effective treatment option for patients...
Dr. Andrés Rodríguez -
Learn More
Arterial Accesses

Hyper-Adducted Right Radial Access vs. Left Radial Access: Aiming for Lower Daily Radiation Exposure

Interventional cardiologists face one of the most extreme occupational hazards: ionizing radiation. The right radial access (RRA)...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

Is Transcarotid Access a Safe Option in TAVI?

Transcatheter aortic valve implantation (TAVI) should preferably be conducted via transfemoral access, according to European guideline (in...
Dr. Carlos Fava -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy